Discovery of EGFR L858R-targeting peptide shows promise against ovarian cancer
Peptide-1 demonstrates strong binding affinity to EGFR L858R and antiproliferative activity against ovarian cancer cells.
Asset / Drug
Drug and asset intelligence for SKOV3 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.